Fact CheckerSign in

NCT05494359Completed

The Diagnostic Value of Nitrogen Element (N) in Esophagus Cancer

The Diagnostic Value of Various Mass Nitrogen Components Excreting for Oral Gas in Esophagus Cancer

Source: ClinicalTrials.gov · Last updated 14 Jul 2025

Brief summary (registry, in English)

The purpose of this study is to determine the diagnostic value of various nitrogen components in oral gas for esophagus cancer (ESCA) .

Status (registry)
Completed
Study type
Observational
Enrollment
120 (actual)
First submitted
7 Aug 2022
Start date
Apr 2023
Primary completion date
Nov 2024
Lead sponsor
Hepatopancreatobiliary Surgery Institute of Gansu Province
NCT number
NCT05494359

What you commit to

  • Study type: Observational
  • Participants enrolled: 120
  • From Apr 2023 to the primary completion date, Nov 2024
  • 3 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Esophageal or gastric surgery
  • History of previous upper abdominal surgery
  • History of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal dissection
  • History of previous neoadjuvant chemotherapy or radiotherapy
  • Long-term Chinese medicine treatment of unknown drug nature

Other illness

  • History of other malignant disease within past five years
  • History of unstable angina or myocardial infarction within past six months
  • History of cerebrovascular accident within past six months
  • Requirement of simultaneous surgery for other disease
  • Emergency surgery due to complication (bleeding, obstruction or perforation) caused by cancer
  • Severe mental disorder

Lab values

  • Unstable vital signs Coagulation dysfunction (INR\>1.5)
  • Low peripheral blood platelet or using anti coagulation drugs

Other

  • Pregnant women or breastfeeding
  • Unwillingness or inability to consent for the study

Who the study is looking for

  • Esophageal cancer patients (Case): Subject diagnosed with ESCA based on typical clinical symptoms, endoscopic observation of esophageal lesions, and histopathological examination of biopsy specimens obtained from the lesion sites.
  • Reflux esophagitis patients (Case control): Subject diagnosed diagnosed with reflux esophagitis based on typical clinical symptoms (e.g., heartburn and acid regurgitation) and endoscopic evidence of esophageal mucosal injury classified according to the Los Angeles classification system (Grade A: mucosal breaks ≤5 mm in length; Grade B: mucosal breaks \>5 mm in length but not confluent; Grade C: confluent mucosal breaks involving \<75% of the esophageal circumference; Grade D: confluent mucosal breaks involving ≥75% of the esophageal circumference).
  • Health people: (Healthy control): no history of malignant tumors within the past five years, normal findings on gastroscopy, with no evidence of esophageal or gastric lesions, no history of gastrointestinal diseases such as gastroesophageal reflux disease (GERD) or Barrett's esophagus, blood counts, tumor biomarkers, and liver and kidney function tests within normal ranges.

Age in the registry: 18 years to 80 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (3)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Hepatopancreatobiliary Surgery Institute of Gansu Province
Coordinator of this site? Confirm its status
LanzhouChinaUnknown status
Clinical Research Centre, The Seventh Affiliated Hospital
Coordinator of this site? Confirm its status
ShenzhenChinaUnknown status
Wuwei Tumor Hospital
Coordinator of this site? Confirm its status
WuweiChinaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.